A Gram Research analysis of 66 clinical bacterial samples found that the probiotic Lacticaseibacillus rhamnosus reduced protective biofilm structures in antibiotic-resistant Pseudomonas aeruginosa by more than 50% and decreased biofilm-related gene expression significantly. The probiotic showed dose-dependent effectiveness, working better at higher concentrations, though this laboratory research hasn’t yet been tested in humans.
Scientists discovered that a common probiotic called Lacticaseibacillus rhamnosus can fight a dangerous bacteria called Pseudomonas aeruginosa that resists many antibiotics. In lab tests, the probiotic successfully broke down protective layers (called biofilms) that the bacteria use to hide from medicine. The bacteria tested were from real patients and showed high antibiotic resistance. When researchers treated these bacteria with the probiotic at higher concentrations, it reduced the bacteria’s ability to form these protective shields by more than 50%. This research suggests probiotics might offer a new way to help treat infections that antibiotics alone can’t defeat.
Key Statistics
A 2026 laboratory study of 66 clinical Pseudomonas aeruginosa isolates found that 87.9% demonstrated strong biofilm-forming capacity, with nearly all showing resistance to multiple antibiotics.
Treatment with the probiotic Lacticaseibacillus rhamnosus at 25% and 50% concentrations reduced the expression of five key biofilm-formation genes by more than 50% in multidrug-resistant bacterial isolates, according to real-time PCR analysis.
Scanning electron microscopy confirmed that the probiotic L. rhamnosus caused structural disruption of bacterial biofilms in a dose-dependent manner, with effects increasing at higher probiotic concentrations.
The Quick Take
- What they studied: Can a probiotic bacteria called L. rhamnosus stop a dangerous germ called Pseudomonas aeruginosa from building protective shields that make it hard to kill with antibiotics?
- Who participated: 66 samples of Pseudomonas aeruginosa bacteria collected from real patients. These bacteria were resistant to many common antibiotics and had strong biofilm-forming abilities.
- Key finding: The probiotic successfully reduced the bacteria’s protective biofilm structures by more than 50% and decreased the expression of genes that help bacteria form these shields.
- What it means for you: This research suggests probiotics might become a helpful tool alongside antibiotics for treating stubborn infections, especially in people with weakened immune systems. However, this is early-stage lab research and more human testing is needed before doctors can use this approach clinically.
The Research Details
Researchers collected 66 samples of Pseudomonas aeruginosa bacteria from patients in clinical settings. They first tested how resistant these bacteria were to common antibiotics and measured how well they could form biofilms—protective layers that bacteria create to shield themselves from medicine.
Next, they exposed these bacteria to different concentrations of a probiotic strain called Lacticaseibacillus rhamnosus. They used laboratory tests to measure how well the probiotic killed the bacteria and broke down their protective biofilm shields. They also used advanced microscopy to visually confirm that the biofilm structures were actually being destroyed.
Finally, they used genetic testing (real-time PCR) to measure whether the probiotic reduced the activity of specific genes that bacteria use to build and maintain their protective biofilms. This helped them understand exactly how the probiotic was working at a molecular level.
This research approach is important because it bridges the gap between basic science and real-world medical problems. By testing against actual patient samples rather than just laboratory strains, the findings are more likely to be relevant to real infections. The combination of multiple testing methods—killing tests, microscopy, and genetic analysis—provides strong evidence that the probiotic works through multiple mechanisms.
Strengths: The study used real clinical isolates from patients, tested multiple concentrations of the probiotic, and confirmed results using three different scientific approaches. Limitations: This is laboratory research only—no human trials have been conducted yet. The study doesn’t specify exactly how many different patients these 66 samples came from, and it doesn’t test whether this approach would work inside the human body where conditions are very different from a lab dish.
What the Results Show
Among the 66 bacterial samples tested, 87.9% showed strong biofilm-forming ability, and nearly all demonstrated resistance to multiple antibiotics. When treated with the probiotic L. rhamnosus at concentrations of 25% and 50%, the bacteria showed significant reductions in both their ability to survive and their ability to form protective biofilms.
The effects were dose-dependent, meaning higher concentrations of the probiotic worked better than lower ones. The probiotic’s killing power also increased with higher bacterial cell density, suggesting it becomes more effective when facing larger populations of bacteria.
Microscopy images showed that the probiotic actually destroyed the physical structure of the biofilms—the protective shields that bacteria hide behind. Genetic testing revealed that the probiotic reduced the activity of five key genes involved in biofilm formation by more than 50%, explaining how it was achieving these protective effects.
These results suggest the probiotic works through multiple pathways: directly killing bacteria, breaking down their protective structures, and silencing the genes that help them build these shields.
The study found that the probiotic’s effectiveness was consistent across different types of multidrug-resistant P. aeruginosa isolates, suggesting it might work against various strains of this bacteria. The dose-dependent response indicates that doctors might be able to adjust probiotic concentrations to optimize treatment effectiveness.
This research adds to growing evidence that probiotics can fight antibiotic-resistant bacteria through mechanisms beyond direct killing. Previous studies have shown probiotics can compete with harmful bacteria for resources and produce compounds that inhibit growth. This study is notable for demonstrating that probiotics can specifically target biofilm formation—a major reason why antibiotic-resistant infections are so difficult to treat.
This study was conducted entirely in laboratory dishes, not in living organisms. The human body has immune systems, different pH levels, and competing bacteria that could change how well this probiotic works. The study doesn’t tell us whether eating or taking this probiotic would actually help patients with real infections. Additionally, the research doesn’t explore potential side effects or whether the probiotic could cause problems in immunocompromised patients who might benefit most from this treatment. More research in animal models and eventually human trials would be needed before this could become a medical treatment.
The Bottom Line
Based on this laboratory research, L. rhamnosus shows promise as a potential complementary treatment alongside antibiotics for antibiotic-resistant Pseudomonas aeruginosa infections. However, confidence in clinical application is currently low because human studies haven’t been conducted. This research suggests further investigation is warranted, particularly in immunocompromised patients where treatment options are limited.
This research is most relevant to: patients with chronic antibiotic-resistant Pseudomonas infections (like some cystic fibrosis patients), immunocompromised individuals prone to serious infections, and healthcare providers treating multidrug-resistant bacterial infections. This is NOT a recommendation for people to self-treat with probiotics—clinical guidance from a doctor is essential.
If this approach moves to human testing, realistic timelines would be: 2-3 years for animal studies, 3-5 years for early human safety trials, and 5-10 years before this could potentially become a standard treatment option. This is early-stage research, so benefits are theoretical at this point.
Frequently Asked Questions
Can probiotics kill antibiotic-resistant bacteria?
Laboratory research shows the probiotic L. rhamnosus can reduce antibiotic-resistant Pseudomonas aeruginosa by disrupting their protective biofilm shields and reducing biofilm-related genes by over 50%. However, this is early-stage research—human studies haven’t been conducted yet.
What is a bacterial biofilm and why is it dangerous?
A biofilm is a protective slimy layer bacteria create to shield themselves from antibiotics and immune system attacks. Biofilms make infections much harder to treat because antibiotics can’t penetrate the shield effectively, allowing bacteria to survive treatment.
Should I take probiotics if I have a Pseudomonas infection?
This laboratory research doesn’t yet support using probiotics as a treatment for Pseudomonas infections. Always follow your doctor’s treatment recommendations. Discuss emerging probiotic research with your healthcare provider before trying any new approaches.
When will probiotics be available as a treatment for antibiotic-resistant infections?
This research is in early stages. Animal studies would likely take 2-3 years, followed by human safety trials lasting 3-5 years. Clinical availability would realistically be 5-10 years away if development continues successfully.
Why is Pseudomonas aeruginosa so dangerous?
P. aeruginosa is an opportunistic pathogen that causes serious infections in immunocompromised patients. It resists many antibiotics and forms protective biofilms, making infections extremely difficult to treat with standard medications.
Want to Apply This Research?
- Users with chronic Pseudomonas infections could track infection markers (sputum production, lung function tests, infection frequency) monthly to monitor disease progression, which would be relevant if probiotic treatments become available.
- While this research doesn’t yet support probiotic supplementation for P. aeruginosa infections, users could use the app to maintain a detailed infection log and antibiotic history to share with their healthcare provider, supporting informed discussions about emerging treatment options.
- Set up quarterly check-ins to review infection frequency, antibiotic effectiveness, and quality of life metrics. This baseline data would be valuable if users want to discuss experimental probiotic approaches with their doctor or participate in future clinical trials.
This research represents early-stage laboratory findings and has not been tested in humans. Pseudomonas aeruginosa infections are serious medical conditions requiring professional medical care. Do not attempt to self-treat with probiotics or other supplements without explicit guidance from your healthcare provider. This article is for educational purposes only and should not replace medical advice from a qualified physician. If you have a chronic Pseudomonas infection or are immunocompromised, consult your doctor before making any changes to your treatment plan.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.